The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Lymphoma

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies

Leuk Lymphoma

Grunblatt E, Meng Z, Baldridge AS, Patel NP, Stanisic A, Feinstein MJ, Rao A, Gordon LI, Winter JN, Ma S, Mehta J, Singhal S, Karmali R, Akhter N

doi: 10.1080/10428194.2024.2448713

Multiple Myeloma (MM)

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Br J Haematol

Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N, Duffy C, Costello P, Cruz JD, Looka A, Nohria A

doi: 10.1111/bjh.70216

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

Lymphoma

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Blood Cancer J

Dulobdas V, Kirkwood AA, Serpenti F, Gautama B, Panopoulou A, Mathew A, Gabriel S, Malladi R, Pealing J, Bonney D, Nicholson E, Besley C, Ghorashian S, Kuhnl A, Davies E, Chappell J, Black A, Menne T, O'Reilly MA, Sanderson R, Chaganti S

doi: 10.1038/s41408-025-01225-9

Multiple Myeloma (MM)

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Blood

Korst CLBM, Tahri S, Duetz C, Bruins WSC, de Jonge AV, de Jong MME, Fokkema C, Smits F, Groen K, Verkleij CPM, Frerichs KA, Papazian N, van Duin M, van Beek G, Hoogenboezem R, Baardemans T, Dal Collo G, Stoetman ECG, Cosovic M, Twickler I, Rentenaar R, Eken M, Homan-Weert PM, Saraci E, D'Agostino M, van der Velden VHJ, Sanders MA, Gay F, Broijl A, Moreau P, Sonneveld P, Zweegman S, Mutis T, Cupedo T, van de Donk NWCJ

doi: 10.1182/blood.2024026455

Multiple Myeloma (MM)

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

Blood

Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S

doi: 10.1182/blood.2025029773

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Lymphoma

Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

Hemasphere

Ossami Saidy A, Peczynski C, Thieblemont C, Daskalakis M, Wehrli M, Beauvais D, Finke J, Schorb E, Vandenberghe P, Berning P, Stelljes M, Ayuk F, Ram R, Von Bonin M, Dreger P, Bethge W, Kuhnl A, Jost L, Stölzel F, von Tresckow B, Renner C, Fuhrmann S, Galimard JE, Michel E, Bazarbachi A, Balari AS, Schmitz N, Glass B

doi: 10.1002/hem3.70146

Multiple Myeloma (MM)

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood

Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, von Tresckow B, Wulf GG, Weisel KC, Blau I, Engelhardt M, Wäsch R, Schub N, Teipel R, Hecker JS, Waldschmidt JM, Besemer B, Baermann BN, Call S, Hansmann L, Ayuk FA, Raab MS, Einsele H, Platzbecker U, Kröger N

doi: 10.1182/blood.2025028330

Related content

Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Expanding the Curative Potential of CAR T-Cell Therapy

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST